Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pischon, T.
Right arrow Articles by Sharma, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pischon, T.
Right arrow Articles by Sharma, A. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 14-17
© 2001 European Renal Association-European Dialysis and Transplant Association

Editorial Comments

Obesity as a risk factor in renal transplant patients

Tobias Pischon and Arya M. Sharma

Franz-Volhard-Klinik, Department of Nephrology and Hypertension, Universitätsklinikum Charité, Berlin, Germany

Keywords: graft survival; obesity; renal transplantation; risk factor

Introduction

Obesity, defined as a body-mass index (BMI)>30 kg/m2, is a widespread disorder that currently affects as many as 20% of the adult population in industrialized countries [1]. Increased body weight is a well-established risk factor for a variety of conditions including hypertension and type 2 diabetes [2]. Recently, the importance of obesity was also underscored by the fact that the American Heart Association now considers obesity a major risk factor for ischaemic heart disease [3]. Furthermore, surgical procedures in obese individuals are associated with an increased risk both for intraoperative complications and wound-related problems [4].

Renal transplantation is currently considered the treatment of choice for most patients with end-stage renal failure. However, availability of organs is limited and therefore, selection of patients who are likely to have a positive outcome remains an important issue. Based on previous studies and local experience, . . . [Full Text of this Article]

Characteristics of the identified studies

Definition and prevalence of obesity

Patient mortality

Post-transplant complications

Acute rejection and delayed graft function

Graft survival

Weight gain

Conclusions

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nutr Clin PractHome page
J. W. Alexander and H. Goodman
Gastric Bypass in Chronic Renal Failure and Renal Transplant
Nutr Clin Pract, February 1, 2007; 22(1): 16 - 21.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
A. Ahmed, A. Husain, T. E. Love, G. Gambassi, L. J. Dell'Italia, G. S. Francis, M. Gheorghiade, R. M. Allman, S. Meleth, and R. C. Bourge
Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods
Eur. Heart J., June 2, 2006; 27(12): 1431 - 1439.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
E. J. Kruep and L. E. Basskin
Cost-minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting
Am. J. Health Syst. Pharm., December 15, 2005; 62(24): 2597 - 2603.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
J. W. Fisher
Erythropoietin: Physiology and Pharmacology Update
Experimental Biology and Medicine, January 1, 2003; 228(1): 1 - 14.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
C. Fourtounas
Evidence-based or stock market-driven nephrology?
Nephrol. Dial. Transplant., April 1, 2002; 17(4): 690 - 691.
[Full Text] [PDF]